Work

The value of early diagnosis and treatment in Parkinson's disease: a literature review of the potential clinical and socioeconomic impact of targeting unmet needs in Parkinson’s disease

Year: 2016
Type: book
Abstract: Parkinson's disease (PD) is a chronic progressive neurodegenerative disease affecting approximately 7 million people globally, with devastating effects on quality of life and severe socioeconomic consequences on individuals, their families and society.Worryingly the global prevalence of PD continues to increase-without any available disease slowing therapy or cure to date, the approved treatment allows to ameliorate the symptoms patients endure.Therefore, the targeting of unmet needs in the management of PD grows more crucial, not only to help patients live with their disease, but also in addressing the increasing socioeconomic burden of the disease and to ensure sustainability in the treatment of this chronic condition.This report sheds light on two sides of Parkinson's disease and its diagnosis: the evidence to support the need for early, if not prodromal, diagnosis and better symptomatic and preventive treatment, and the potential clinical and socioeconomic impact of targeting unmet needs.Since misdiagnosed, delayed or entirely missed identification of PD still occurs in parts of Europe, it is vital to search for and define a simple, easy to use, widely available and cost-effective diagnostic test.New developments of diagnostic tools for prodromal and early stage PD are encouraged, and, if established, should fast be utilised by medical professionals.A growing body of evidence from the medical literature describes numerous advantages of early symptomatic therapeutic intervention in PD.Nevertheless, so far clinical trials have failed to convincingly show that presently approved drugs are able to slow down disease progression.However, there is hope, as efforts in drug development over the last 20 years -focusing on the etiopathogenesis of PD -provide the first substances with a disease modifying potential for PD, and these compounds will enter early clinical testing in 2017.This report takes the forefront position to be used as an important source of information for healthcare managers, as well as policy and practitioner stakeholders, to highlight the extreme urgency of early, if not preclinical, diagnosis and treatment of PD.Furthermore, it confirms that early diagnosis and treatment are paramount to reducing the risk of disease progression, limiting the effects of PD on quality of life, and potentially lowering long-term treatment costs.Adherence to now available treatment plans by patients and disease-management strategies by medical practitioners through the implementation of a chronic model of care is important to improve treatment adherence and rates of correct diagnosis.Clinicians should be properly informed regarding stringent diagnostic approaches in order to ensure diagnosis is performed appropriately and accurately.This study is part of a broader investigation by the European Brain Council (EBC) on the cost of nontreatment and patient journey analysis, the Value of Treatment project 2015-2017.The project aims at developing and applying to brain disorders a new integrated care model framework and therefore promotes a more holistic management of chronic conditions in Europe, including PD.By providing an extensive review of the case for Parkinson's disease, the report sheds light on the crucial needs for the development of improved symptomatic therapy -and even more important -any disease modifying treatments for PD.This report provides a robust set of data and calls to action for meeting the ultimate challenge: to find a cure for PD.
Language: English
Field: Medicine
Open Access status: green
OpenAlex ID: W2580135716
FWCI: 3.045
Cites: 111
Cited by: 47
Related to: 10